Revolution Medicines’ FDA approval for its oral pancreatic cancer therapy highlighted a disconnect between clinical milestones and near-term equity reaction. The FDA cleared Rasonque (daraxonrasib) as a targeted treatment for metastatic pancreatic ductal adenocarcinoma after at least one prior systemic therapy, with breakthrough and priority review acceleration. Despite the “historic” approval framing, the company’s shares stayed largely flat for the week, with investors weighing pricing and commercial assumptions alongside broader market volatility. The stock moved up slightly early, then fell on profit-taking and a down day for major markets. For biotech finance teams, the key signal is how approval mechanics (priority review, vouchers, Breakthrough Therapy and Orphan Drug) may not override valuation sensitivity to pricing strategy and revenue timing.